99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
Status:
Terminated
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF
received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128. The
first dose was administered on Day 1, and the second dose on Day 42 (±2 weeks).
All patients were to start a new disease modifying treatment for RA or AS on Day 2. This
disease modifying treatment was at the discretion of the investigator and was not chosen by
the sponsor.
Safety was monitored at every visit. Whole body scintigraphic imaging was performed at Day 1
and Day 42 after 99mTc-rhAnnexin V-128 dosing. Clinical disease assessments were performed at
screening, Day 42 and Day 90 to assess response to RA or AS treatment. Blood was drawn to
test for 99mTc-rhAnnexin V-128 immunogenicity at screening and on Days 30, 56 and 90.
Patients participating in the pharmacokinetic (PK)/dosimetric sub-study had additional
assessments in the 24 hours following the Day 1 dose of 99mTc-rhAnnexin V-128.